PRECISION BIOSCIENCES INC — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precision BioSciences dosed the first patient with PBGENE-DMD (Duchenne muscular dystrophy) in August 2026 at Arkansas Children's Hospital, with initial safety data targeted for year-end 2026. PBGENE-HBV will present late-breaking oral data at AASLD Liver Meeting on November 8, 2026. Cash position of $108.0M (up from $137.2M at year-end 2025) provides runway through 2028; Q3 2026 R&D expenses were $12.7M versus $13.4M prior year.
Why this rating
Two major clinical programs in execution phase with meaningful cash runway; first DMD patient dosed is milestone. Relative to $47.1M market cap, $108M cash is 2.3x capitalization—substantial. Data readouts and program milestones material for small-cap biotech trajectory.
Price action (we called it positive)
before filing · preread $6.95 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.